Drugs / CartiLife
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03517046 | Jul 2012 → Dec 2013 | articular cartilage disorder | Biosolution Co., Ltd. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04744402 | Oct 2020 → Dec 2023 overdue | articular cartilage disorder | Biosolution Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT03545269 | Feb 2014 → Feb 2017 | articular cartilage disorder | Biosolution Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05051332 | Mar 2020 → Sep 2023 | articular cartilage disorder | Biosolution Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CartiLife | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03545269 ↗ |
| Modality | Cell therapy | “developed from autologous chondrocytes” NCT03517046 ↗ |
| Route | Other | “through injection with a fibrin adhesive through minimal arthrotomy” NCT03517046 ↗ |